Digital health technologies in the accelerating medicines Partnership® Schizophrenia Program

Although meta-analytic studies have shown that 25-33% of those at Clinical High Risk (CHR) for psychosis transition to a first episode of psychosis within three years, less is known about estimating the risk of transition at an individual level. Digital phenotyping offers a novel approach to explore the nature of CHR and may help to improve personalized risk prediction. Specifically, digital data enable detailed mapping of experiences, moods and behaviors during longer periods of time (e.g., weeks, months) and offer more insight into patterns over time at the individual level across their routine daily life. However, while novel digital health technologies open up many new avenues of research, they also come with specific challenges, including replicability of results and the adherence of participants. This paper outlines the design of the digital component of the Accelerating Medicines Partnership® Schizophrenia Program (AMP SCZ) project, a large international collaborative project that follows individuals at CHR for psychosis over a period of two years. The digital component comprises one-year smartphone-based digital phenotyping and actigraphy. Smartphone-based digital phenotyping includes 30-item short daily self-report surveys and voice diaries as well as passive data capture (geolocation, on/off screen state, and accelerometer). Actigraphy data are collected via an Axivity wristwatch. The aim of this paper is to describe the design and the three goals of the digital measures used in AMP SCZ to: (i) better understand the symptoms, real-life experiences, and behaviors of those at CHR for psychosis, (ii) improve the prediction of transition to psychosis and other health outcomes in this population based on digital phenotyping and, (iii) serve as an example for replicable and ethical research across geographically diverse regions and cultures. Accordingly, we describe the rationale, protocol and implementation of these digital components of the AMP SCZ project. **Link to video interview: https://vimeo.com/1060935583 *.

Authors

Institutions

Publication Details

Journal
Schizophrenia
Published
2025-06-03
DOI
https://doi.org/10.1038/s41537-025-00599-w
Citations
9
Primary Topic
Digital Mental Health Interventions
Type
article
Field-Weighted Citation Impact
13.90

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Digital health technologies in the accelerating medicines Partnership® Schizophrenia Program

Matcheri S. Keshavan, Phillip Wolff, Sylvain Bouix, Celso Arango et al.
9 citations
Schizophrenia
Digital Mental Health Interventions
13.90
article

Digital health technologies in the accelerating medicines Partnership® Schizophrenia Program

Matcheri S. Keshavan, Phillip Wolff, Sylvain Bouix, Celso Arango, Barbara A. Cornblatt, John M. Kane, Justin Nathaniel Baker, Diana O. Perkins, Jai L. Shah, Andrew Jin Soo Byun, Albert R. Powers, Godfrey D. Pearlson, Carrie E. Bearden, Fred W. Sabb, Kerstin Langbein, Nicholas J. K. Breitborde, Jason Eric Schiffman, Gregory P. Strauss, Jijun Wang, Philippe Conus, Daniel H. Mathalon, Luis Alameda, Walid Yassin, Anastasia Haidar, Swapna Verma, Jessica Hartmann, Lana Kambeitz‐Ilankovic, John Blake Torous, Dominic Dwyer, René S. Kahn, Matthew R. Broome, Habiballah Rahimi-Eichi, Priya Matneja, Johanna T. W. Wigman, Covadonga M. Díaz‐Caneja, Merete Nordentoft, Steven M. Silverstein, Jack Rogers, Isabelle Scott, Carla Gerber, Ofer Pasternak, Yoonho Chung, Christy Lai Ming Hui, Barnaby Nelson, Pablo A. Gaspar, Judy L. Thompson, Jean Addington, Cheryl M. Corcoran, Jesús Pérez, Rachel Upthegrove, William S. Stone, Patrick D. McGorry, Carsten Langholm, Paolo Fusar‐Poli, Zailyn Tamayo, Monica E. Calkins, Laura M. Rowland, Aditya Vaidyam, Scott W. Woods, Stefan Smesny, Kristin S. Cadenhead, Ann Ee Ching, Martha E. Shenton, Daniel H. Wolf, Joseph Kambeitz, Vijay Anand Mittal, Leslie E. Horton, Jimmy Choi, Nikolaos Koutsouleris, Owen Borders, Kang Ik K. Cho, Sung‐Wan Kim, Eric Yu Hai Chen, Louise Birkedal Glenthøj, Ángela Núñez, Erlend Lane, Lauren M. Ellman, Adibah Amani Nasarudin
article en
9 citations

Abstract

Although meta-analytic studies have shown that 25-33% of those at Clinical High Risk (CHR) for psychosis transition to a first episode of psychosis within three years, less is known about estimating the risk of transition at an individual level. Digital phenotyping offers a novel approach to explore the nature of CHR and may help to improve personalized risk prediction. Specifically, digital data enable detailed mapping of experiences, moods and behaviors during longer periods of time (e.g., weeks, months) and offer more insight into patterns over time at the individual level across their routine daily life. However, while novel digital health technologies open up many new avenues of research, they also come with specific challenges, including replicability of results and the adherence of participants. This paper outlines the design of the digital component of the Accelerating Medicines Partnership® Schizophrenia Program (AMP SCZ) project, a large international collaborative project that follows individuals at CHR for psychosis over a period of two years. The digital component comprises one-year smartphone-based digital phenotyping and actigraphy. Smartphone-based digital phenotyping includes 30-item short daily self-report surveys and voice diaries as well as passive data capture (geolocation, on/off screen state, and accelerometer). Actigraphy data are collected via an Axivity wristwatch. The aim of this paper is to describe the design and the three goals of the digital measures used in AMP SCZ to: (i) better understand the symptoms, real-life experiences, and behaviors of those at CHR for psychosis, (ii) improve the prediction of transition to psychosis and other health outcomes in this population based on digital phenotyping and, (iii) serve as an example for replicable and ethical research across geographically diverse regions and cultures. Accordingly, we describe the rationale, protocol and implementation of these digital components of the AMP SCZ project. **Link to video interview: https://vimeo.com/1060935583 *.

SchizophreniaVol. 11(1)
Rutgers, The State University of New Jersey (US), Chonnam National University (KR), Northwestern University (US), University of North Carolina at Chapel Hill (US), University of Copenhagen (DK), Brigham and Women's Hospital (US), Hartford Hospital (US), Northwell Health (US), Beth Israel Deaconess Medical Center (US), Feinstein Institute for Medical Research (US), University Medical Center Groningen (NL), Harvard University (US), Emory University (US), University of California, Los Angeles (US), University of Georgia (US), The University of Melbourne (AU), University of Calgary (CA), University of Pittsburgh (US), Douglas College (CA), University of California, San Francisco (US), University of Cologne (DE), King's College London (GB), Universidad de Salamanca (ES), University of California, Irvine (US), Washington University in St. Louis (US), Heidelberg University (DE), University of Pavia (IT), PeaceHealth St. John Medical Center (US), Mental Health Services (DK), McLean Hospital (US), Instituto de Salud Carlos III (ES), University Hospital Heidelberg (DE), Copenhagen University Hospital (DK), Shanghai Mental Health Center (CN), University of Rochester Medical Center (US), Hospital General Universitario Gregorio Marañón (ES), Yale University (US), University of California San Diego (US), Centro de Investigación Biomédica en Red de Salud Mental (ES), Hôpital de Cery (CH), Central Institute of Mental Health (DE), Donald & Barbara Zucker School of Medicine at Hofstra/Northwell (US), Orygen (AU), Hôpital Orthopédique de la Suisse Romande (CH), Instituto de Investigación Biomédica de Salamanca (ES), Jena University Hospital (DE), Behavioral Health Network (US), Institute of Mental Health (SG), San Francisco VA Health Care System (US), Cambridgeshire and Peterborough NHS Foundation Trust (GB), University Hospital Cologne (DE), Birmingham Women’s and Children’s NHS Foundation Trust (GB), Connecticut Mental Health Center (US), National Institute of Mental Health (US), Hotchkiss Brain Institute (CA), McGill University (CA), The Ohio State University (US), University of Chile (CL), University of Pennsylvania (US), University of Birmingham (GB), Temple University (US), University of Hong Kong (HK), École de Technologie Supérieure (CA), Icahn School of Medicine at Mount Sinai (US)
Pfizer, Biogen, Teva Pharmaceutical Industries, Sunovion, Indivior, Gedeon Richter, Ministerio de Ciencia e Innovación, Servier, H. Lundbeck A/S, HLS Therapeutics, National Institutes of Health, Allergan, Instituto de Salud Carlos III, National Institute of Mental Health, Cilag
Partnerships for the goals
Openalex Percentile: Top 1%
Digital Mental Health Interventions
13.90
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.